The clinical trials listed on this page are not specifically designed for fibrolamellar carcinoma, but include FLC patients based on eligibility criteria (basket trials or broader liver cancer studies).
Trials Currently Recruiting That Include FLC Patients
● I‑PREDICT (Molecularly Guided Therapy Study)
- Formal name: Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses (MCW I-PREDICT)
- Trial type: Includes fibrolamellar carcinoma (precision oncology)
- Phase: Phase I / II
- Recruitment status: Active, Recruiting
- Eligible ages: 18 years and older
- Location: Milwaukee, WI (Medical College of Wisconsin)
- ClinicalTrials.gov ID: NCT05674825
- Detail page: [View trial details]
This phase I trial assesses the use of molecular profile data to identify individualized cancer therapies for patients with aggressive malignancies.
● Checkpoint Inhibition in Pediatric Hepatocellular Carcinoma
- Formal name: Checkpoint Inhibition in Pediatric Hepatocellular Carcinoma
- Trial type: Includes fibrolamellar carcinoma
- Phase: Phase II
- Recruitment status: Active, Recruiting
- Eligible ages: Up to 30 years
- Location: Boston, MA (Dana‑Farber Cancer Institute), plus sites in California, Ohio, and Texas
- ClinicalTrials.gov ID: NCT04134559
- Detail page: [View trial details]
This phase II study evaluates the effectiveness of the immunotherapy drug pembrolizumab as a treatment for pediatric hepatocellular carcinoma.
Important Notes
- These trials are not FLC‑specific, and eligibility criteria vary.
- Patients should consult their oncology team to determine suitability.
- Trial status and enrollment availability may change at any time; please visit clinicaltrials.gov for a comprehensive list of active trials.
The Fibrolamellar Cancer Foundation does not provide medical advice. We provide website users with information to help them better understand their health conditions and current approaches towards diagnosis, treatment and supportive care. Always seek the advice of your physician or other qualified healthcare provider.